滚动资讯
FierceBiotechLilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitorsWatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn LaFierceBiotech麦克森以12.5亿美元将外科部门少数股权置换给阿波罗基金。FierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industryFierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1BBioWorldAppointments and advancements for April 22, 2026BioWorldFinancings for April 22, 2026BioWorldIn the clinic for April 22, 2026BioWorldOther news to note for April 22, 2026BioWorldRegulatory actions for April 22, 2026Thermo FisherGlobal Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation - PR Newswire
Pharmaron 2026年3月11日

Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma

Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma

原文
暂时没有全文，请查看原始来源。